肠道：被遗忘的智慧器官 / The Gut: Our Forgotten Organ of Wisdom

1988年一个寻常的悉尼夏日，在距离市中心不到十公里的圣乔治医院（St. George Hospital）里，一位中年女性患者躺在病床上，眼神中流露出一种难以名状的神情——那是绝望与希望交织的复杂情绪。她已经与抑郁症抗争了将近二十年，尝试过几乎所有可用的治疗方案：从选择性5-羟色胺再摄取抑制剂（SSRIs）到认知行为疗法，从电休克治疗到住院强化护理。病情如同顽固的暗流，在短暂的好转后总会卷土重来，将她一次次拖入深渊的边缘。然而，正是这位已经对生活丧失信心的患者，将成为医学史上一个重要时刻的见证者和参与者——她即将接受一种在当时看来近乎荒诞的治疗方法：粪便微生物移植（Fecal Microbiota Transplantation, FMT）。

为她实施这一治疗的是澳大利亚胃肠病学家托马斯·博罗迪（Thomas Borody），一位在悉尼行医的消化系统疾病专家。博罗迪在当时的学术圈并非籍籍无名之辈，但他的研究方向——肠道微生物与难治性疾病之间的关联——在那个时代仍被视为边缘领域的主流医学研究者们更倾向于关注肠道微生物在感染性腹泻中的作用，而对它们可能影响大脑功能和情绪的假说嗤之以鼻。然而，正是这种被视为“异端”的研究方向，最终撬动了一个价值数百亿美元的产业，催生了无数临床试验，并彻底改变了人类对“自我”的认知。

当博罗迪将来自健康供体的粪便悬液通过鼻胃管缓慢注入这位女性患者的消化道时，他或许并未预见到，这一在当时被同行嘲笑为“粪便疗法”的尝试，会在三十五年后成为《新英格兰医学杂志》（New England Journal of Medicine）年度突破性疗法的有力候选。更重要的是，这位患者的抑郁症状在接下来的数周内出现了显著改善——不是部分缓解，而是近乎戏剧性的逆转。她重新找回了对生活的兴趣，能够与家人正常交流，甚至开始规划未来的工作与旅行。这一病例，如同一颗投入死水的石子，在医学界激起了层层涟漪，最终汇聚成一场关于肠脑轴（gut-brain axis）的科学革命。

In 1988, on an ordinary summer day in Sydney, Australia, a middle-aged woman lay in a hospital bed at St. George Hospital, less than ten kilometers from the city center. Her eyes reflected an ineffable emotion—the complex intertwining of despair and hope. She had battled depression for nearly two decades, having tried virtually every available treatment: from selective serotonin reuptake inhibitors (SSRIs) to cognitive behavioral therapy, from electroconvulsive therapy to intensive inpatient care. Her condition resembled a stubborn undercurrent, always resurging after brief improvements, dragging her repeatedly into the abyss. Yet this very patient, who had lost confidence in life, would become a witness and participant in a pivotal moment in medical history—she was about to undergo a treatment that seemed almost absurd at the time: Fecal Microbiota Transplantation (FMT).

The gastroenterologist who administered this treatment was Thomas Borody, an Australian digestive system specialist practicing in Sydney. Borody was not an unknown figure in the academic circles of his time, but his research direction—the relationship between gut microorganisms and intractable diseases—remained in the marginal domains of mainstream medicine. Most researchers of that era were more inclined to focus on the role of gut microorganisms in infectious diarrhea, dismissing the hypothesis that they might influence brain function and mood as pseudoscience. However, it was precisely this "heterodox" research direction that would eventually撬动 a multi-billion dollar industry, spawn countless clinical trials, and fundamentally transform humanity's understanding of the "self."

When Borody slowly infused a suspension of feces from a healthy donor through a nasogastric tube into this female patient's digestive tract, he perhaps did not foresee that this attempt, derided by colleagues as "fecal therapy," would become a strong candidate for the New England Journal of Medicine's breakthrough therapy of the year thirty-five years later. More significantly, this patient's depressive symptoms showed remarkable improvement in the following weeks—not partial remission, but a near-dramatic reversal. She regained interest in life, could communicate normally with her family, and even began planning future work and travel. This case, like a stone dropped into stagnant water, rippled through the medical community, eventually converging into a scientific revolution regarding the gut-brain axis.

托马斯·博罗迪与微生物移植的开端

要理解博罗迪为何会在1980年代末走上这条在当时看来前途未卜的研究道路，我们需要将时间线稍稍前移，回到更早的医学实践场景。博罗迪在伦敦接受过医学训练，1980年代移居澳大利亚后，他一直在消化系统疾病领域深耕。在他的临床实践中，有一类疾病引起了他特别的关注：复发性艰难梭菌感染（Clostridioides difficile infection, CDI）。艰难梭菌是一种能够引起严重腹泻和结肠炎的细菌，当患者因其他感染使用抗生素治疗后，这种耐药的细菌往往会趁机大量繁殖，导致感染复发。传统的治疗方法——使用针对艰难梭菌的抗生素如万古霉素或甲硝唑——虽然能够控制急性症状，但复发率极高，部分患者甚至经历数十次感染复发，苦不堪言。

博罗迪在治疗这些患者的过程中注意到一个现象：那些同时存在便秘或其他肠道运动功能障碍的患者，其艰难梭菌感染的复发率明显更高。他开始思考一个看似简单却深刻的问题：如果肠道微生物群的平衡被打破导致了艰难梭菌的过度生长，那么恢复微生物群的平衡是否能够从根本上解决这一问题？这一思考引导他走向了一个大胆的假设——用健康人的粪便来重建患者的肠道微生物群。

Thomas Borody and the Origins of Microbiota Transplantation

To understand why Borody embarked on this seemingly uncertain research path in the late 1980s, we need to rewind slightly to earlier medical practice scenarios. Borody received medical training in London and, after moving to Australia in the 1980s, dedicated himself to the field of digestive system diseases. Among the conditions in his clinical practice, one category drew his particular attention: recurrent Clostridioides difficile infection (CDI). Clostridioides difficile is a bacterium capable of causing severe diarrhea and colitis. When patients use antibiotics for other infections, this drug-resistant bacterium often seizes the opportunity to proliferate massively, leading to recurrent infections. Traditional treatments—antibiotics targeting C. difficile such as vancomycin or metronidazole—can control acute symptoms but have extremely high recurrence rates. Some patients experience dozens of recurrent infections, suffering endlessly.

During his treatment of these patients, Borody noticed a phenomenon: patients with concurrent constipation or other intestinal motility dysfunction had significantly higher recurrence rates of C. difficile infection. He began contemplating a seemingly simple yet profound question: if the imbalance of the gut microbiota led to the overgrowth of C. difficile, could restoring the balance of the microbiota fundamentally solve this problem? This thinking led him toward a bold hypothesis—using healthy donors' feces to rebuild the patient's gut microbiota.

1988年对博罗迪来说是一个转折点。在成功治疗了数例复发性艰难梭菌感染后，他开始将这一技术的应用范围扩展到其他与肠道微生物群失调相关的疾病。他首先尝试将FMT用于治疗炎症性肠病（Inflammatory Bowel Disease, IBD），包括溃疡性结肠炎（Ulcerative Colitis, UC）和克罗恩病（Crohn's Disease, CD）。炎症性肠病是一种慢性肠道炎症性疾病，其发病机制涉及遗传因素、免疫因素和环境因素的复杂交互作用。在那个时代，主流的治疗方案集中于抑制免疫反应，如使用糖皮质激素、氨基水杨酸盐或免疫抑制剂，但这些治疗往往伴随着显著的副作用，且无法实现治愈。

博罗迪的思路与主流观点截然不同。他认为，既然炎症性肠病患者的肠道微生物群与健康人存在显著差异，而这些差异可能不仅是疾病的结果，更是疾病的原因，那么通过FMT引入健康人的微生物群，或许能够纠正这种生态失调，从而改善炎症状态。1988年至2000年间，博罗迪和他的团队在澳大利亚进行了大量FMT临床实践，积累了丰富的病例经验。尽管这些早期工作大多以病例报告或小规模队列研究的形式发表在相对小众的期刊上，但它们为后来的随机对照试验（Randomized Controlled Trial, RCT）奠定了重要的临床基础。

1988 marked a turning point for Borody. After successfully treating several cases of recurrent C. difficile infection, he began expanding the application of this technique to other diseases associated with gut microbiota dysbiosis. He first attempted using FMT to treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). IBD is a chronic intestinal inflammatory disease whose pathogenesis involves the complex interplay of genetic factors, immune factors, and environmental factors. In that era, mainstream treatment focused on suppressing immune responses, such as using glucocorticoids, aminosalicylates, or immunosuppressants, but these treatments often came with significant side effects and could not achieve cure.

Borody's approach differed entirely from mainstream views. He believed that since the gut microbiota of IBD patients differed significantly from that of healthy individuals, and these differences might be not only the result but also the cause of the disease, introducing healthy donors' microbiota through FMT might correct this dysbiosis and improve inflammatory conditions. Between 1988 and 2000, Borody and his team conducted extensive FMT clinical practice in Australia, accumulating rich case experience. Although most of these early works were published in relatively obscure journals as case reports or small-scale cohort studies, they laid an important clinical foundation for later Randomized Controlled Trials (RCTs).

被低估的神经网络：肠神经系统的非凡世界

让我们暂时放下博罗迪的故事，将目光转向人类肠道本身的惊人结构。如果将人体的消化道从口腔到肛门完全展开并平铺，其总表面积可达约250至300平方米——这大约是一个网球场面积的一半，或者一套普通公寓的居住面积。然而，肠道的真正惊人之处，并不在于它的物理尺寸，而在于它所包含的神经网络。

人体内存在两个主要的神经网络：一个是位于颅骨内的大脑，另一个是位于消化道壁内的肠道神经系统（Enteric Nervous System, ENS）。肠道神经系统由超过1亿个神经元组成，这一数字超过了脊髓内神经元的总数，甚至可以与某些较低等哺乳动物的大脑神经元数量相媲美。这些神经元分布在两层神经网络中：一层是位于肠道黏膜下方的黏膜下神经丛（Meissner's plexus），另一层是位于肠道平滑肌层之间的肌间神经丛（Auerbach's plexus）。前者主要参与调节肠道分泌和局部血流，后者则负责协调肠道肌肉的收缩和蠕动。

肠道神经系统与中枢神经系统之间的差异远不止于解剖位置。实际上，肠道神经系统具有惊人的自主性——它能够在完全脱离大脑和脊髓的情况下独立运作。有研究者进行过一个令人印象深刻的